In the future, large clinical trials comparing multitarget therapy and CY should be conducted, and the establishment of more effective and safer treatments for anti-MDA5 antibody-positive DM and JDM patients is desired. This evidence concerns the gene IFIH1 and juvenile dermatomyositis.